Ningbo Menovo Pharmaceutical Co., Ltd. (SHA:603538)

Market Cap	8.52B +49.6%
Revenue (ttm)	1.56B +12.8%
Net Income	112.17M +51.6%
EPS	0.36 +47.6%
Shares Out	339.93M
PE Ratio	70.17
Forward PE	n/a
Dividend	0.11 (0.41%)
Ex-Dividend Date	Jul 9, 2026

Volume	54,762,891
Open	26.71
Previous Close	26.70
Day's Range	24.69 - 26.90
52-Week Range	13.55 - 50.28
Beta	-0.05
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 12, 2026

About SHA:603538

Ningbo Menovo Pharmaceutical Co., Ltd. research, develops, produces, and sells pharmaceutical products. The company’s products portfolio includes valsartan, losartan, clopidogrel, perindopril, rosuvastatin calcium, atorvastatin calcium, purin bahrain, and other products. It offers APIs, intermediates, and preparations for the treatment of cardiovascular, central nervous system, gastrointestinal tract, and other therapeutic areas. The company was founded in 2004 and is headquartered in Ningbo, China.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2004
• Employees: 2,370
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 603538

Financial Performance

In 2025, SHA:603538's revenue was 1.50 billion, an increase of 9.49% compared to the previous year's 1.37 billion. Earnings were 102.23 million, an increase of 53.02%.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jul 29, 2026

Data Sources Report a data error